Pretax income is the income that a company earns before paying income taxes. Suven Pharmaceuticals's pretax income for the
three
months ended in Mar. 2024 was ₹709 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was ₹4,057 Mil.
Suven Pharmaceuticals's pretax margin was 28.01%.
During the past 6 years, Suven Pharmaceuticals's highest Pretax Margin was 51.76%. The lowest was 38.59%. And the median was 45.41%.
Suven Pharmaceuticals Pre-Tax Income Historical Data
The historical data trend for Suven Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Suven Pharmaceuticals's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Pharmaceuticals's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Suven Pharmaceuticals's Pre-Tax Income falls into.
Suven Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Suven Pharmaceuticals's Pretax Income for the fiscal year that ended in Mar. 2024 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,057 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Pharmaceuticals (BOM:543064) Pre-Tax Income Explanation
Suven Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 6 years, Suven Pharmaceuticals's highest Pretax Margin was 51.76%. The lowest was 38.59%. And the median was 45.41%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Suven Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Suven Pharmaceuticals (BOM:543064) Business Description
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:543064 has been successfully added to your 